Drugs / DE-120
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02022501 | Jan 2014 → Apr 2016 | age-related macular degeneration | Santen Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02401945 | Apr 2015 → Jun 2016 | age-related macular degeneration | Santen Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DE-120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02401945 ↗ |
| Route | Intravitreal | “single intravitreal injection” NCT02022501 ↗ |